Noveze

NovEze is indicated for:

Primary hypercholesterolemia:

• co-administered with an HMG-CoA reductase inhibitor (statin) is indicated as adjunctive therapy to a diet for patients with primary (heterozygous familial or non-familial) hypercholesterolaemia who do not respond adequately to the treatment with statins alone.
• in monotherapy, it is indicated as adjunctive therapy to a diet for patients with primary (heterozygous familial or non-familial) hypercholesterolaemia for whom statin administration is not considered appropriate or is not tolerated.

Prevention of cardiovascular events:

• indicated to reduce the risk of cardiovascular events of patients with ischemic heart disease (IHD) and a history of acute coronary syndrome (ACS) when added to existing statin therapy or when newly co-administered with statins.

Homozygous familial hypercholesterolemia (HoFH):

• co-administered with statins is indicated as adjunctive therapy to a diet of patients with HoFH. Patients may also receive adjunctive therapy (eg LDL apheresis).